[Androgenic deficit and its treatment in stroke male patients with diabetes mellitus type II].
We have studied 154 men (mean age 61,4+/-4,1 years) with the first hemispheric ischemic stroke. Clinical and laboratory studies have revealed the androgenic deficit in 66,3%, with its frequency higher in patients with diabetes mellitus type II (50 and 26,3%, respectively). Forty-two men with diabetes mellitus type II and acquired androgenic deficit received replacing treatment with testosterone undecanoate in dose 1000 mg intramuscular. The treatment was started one week after the development of stroke, the next injections were given after 6 weeks and then every 12 weeks during 2 years. The control group included 30 males who did not receive androgens. After 2 years from the beginning of treatment, there were the decrease in clinical severity of androgenic deficit, the increase of total and free testosterone levels, and muscle power in the main group compared to the controls. Body mass index, glicated hemoglobin, cholesterol, triglycerides, low density lipoproteins have decreased as well. Secondary stroke has developed in 3 (7,1%) patients of the main group and in 5 (16,6%) controls; 12 (28,6%) patients returned to work in the main group compared to 2 (6,6%) in the control group. The treatment with androgens has a positive effect on risk factors of secondary ischemic stroke. It is an effective method for improvement of social adaptation of men survived after the stroke.
L Iu
LIu
Morgunov
I A
IA
Denisova
T I
TI
Rozhkova
L V
LV
Stakhovskaia
V I
VI
Skvortsova
D000368:Aged; D000728:Androgens / Q000172:deficiency*; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D020249:Hormone Replacement Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000378:metabolism*; D013739:Testosterone / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000728:Androgens; D013739:Testosterone; C010792:testosterone undecanoate